골수이형성증후군 치료 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 치료 유형별, 최종사용자별, 지역별, 경쟁별(2020-2030년)
Myelodysplastic Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By End User, By Region and Competition, 2020-2030F
상품코드:1668103
리서치사:TechSci Research
발행일:2025년 02월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
골수이형성증후군(MDS) 치료 세계 시장은 2024년 29억 5,000만 달러로 평가되며, 예측 기간 동안 6.02%의 CAGR로 2030년에는 42억 달러에 달할 것으로 예상됩니다.
골수이형성증후군은 골수에서의 혈구 생성 기능 장애를 특징으로 하는 혈액 질환군입니다. 적혈구, 백혈구, 혈소판 생산에 영향을 미쳐 다양한 증상과 합병증을 유발합니다. MDS는 주로 노년층에서 발병하지만 연령에 관계없이 발병할 수 있으며, 급성 골수성 백혈병(AML)으로 진행될 수 있기 때문에 종종 백혈병의 전단계로 간주되며, MDS의 정확한 진단과 치료는 수년 동안 큰 진전을 이루었습니다. MDS의 정확한 원인은 아직 밝혀지지 않았지만, 유전자 돌연변이, 특정 화학제품에 대한 노출, 방사선 치료 등이 관련되어 있는 것으로 알려져 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
29억 5,000만 달러
시장 규모 : 2030년
42억 달러
CAGR : 2025-2030년
6.02%
급성장 부문
병원 클리닉
최대 시장
북미
세계 골수이형성증후군 치료 시장은 여러 요인으로 인해 꾸준히 성장하고 있습니다. 세계 인구의 고령화가 진행됨에 따라 골수이형성증후군의 발병률은 증가할 것으로 예상됩니다. 이러한 인구통계학적 변화는 MDS 치료에 대한 수요 증가에 기여하고 있습니다. 의료진과 환자들 사이에서 MDS에 대한 인식이 높아지면서 조기 진단과 조기 개입이 이루어지고 있으며, 이는 시장 성장을 더욱 촉진하고 있습니다. 신흥 경제 국가들은 의료 인프라 개선과 첨단 치료법에 대한 접근성 향상으로 MDS 치료 시장에서 더욱 중요한 시장 진입자로 부상하고 있습니다. 제약사 및 정부 기관의 MDS 연구개발에 대한 지속적인 투자는 혁신적인 치료 옵션을 창출하고 시장을 확대할 것으로 예상됩니다.
세계 골수이형성증후군(MDS) 치료 시장은 최근 몇 년 동안 괄목할 만한 발전을 이루며 이 어려운 질환을 앓고 있는 환자들에게 새로운 희망을 가져다주고 있습니다. 표적 치료, 맞춤 치료, 지지요법의 개선, 지속적인 임상 검사로 인해 MDS 치료의 환경이 변화하고 있습니다. 고령화 인구의 증가와 인식의 향상으로 MDS 치료 시장은 지속적으로 확대될 것이며, 이는 궁극적으로 이 질환과 싸우는 환자들의 삶의 질 향상과 예후 개선으로 이어질 것으로 보입니다.
주요 시장 촉진요인
호흡기질환 유병률 증가로 세계 골수이형성증후군 치료 시장 성장 견인
주요 시장 과제
가격 압력
주요 시장 동향
기술 발전
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 골수이형성증후군 치료 시장 전망
시장 규모 및 예측
금액별
시장 점유율과 예측
치료 유형별(줄기세포 이식, 면역치료, 화학요법, 면역조절제, 항빈혈약, 기타)
최종사용자별(병원 클리닉, 외래 진료 센터, 기타)
지역별
기업별(2024년)
시장 맵
제6장 북미의 골수이형성증후군 치료 시장 전망
시장 규모 및 예측
시장 점유율과 예측
북미 : 국가별 분석
캐나다
멕시코
제7장 유럽의 골수이형성증후군 치료 시장 전망
시장 규모 및 예측
시장 점유율과 예측
유럽 : 국가별 분석
영국
이탈리아
프랑스
스페인
제8장 아시아태평양의 골수이형성증후군 치료 시장 전망
시장 규모 및 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
인도
일본
한국
호주
제9장 남미의 골수이형성증후군 치료 시장 전망
시장 규모 및 예측
시장 점유율과 예측
남미 : 국가별 분석
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 골수이형성증후군 치료 시장 전망
시장 규모 및 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
인수합병(해당되는 경우)
제품 발매(해당되는 경우)
제13장 Porter's Five Forces 분석
산업내 경쟁
신규 참여의 가능성
공급업체의 능력
고객의 능력
대체품의 위협
제14장 경쟁 구도
AbbVie Inc.
Accord Healthcare Limited
Bristol-Myers Squibb Company
Jazz Pharmaceuticals Inc.
Novartis AG
Lupin Limited
Otsuka America Pharmaceutical Inc.
Takeda Pharmaceutical Company Limited
Astex Therapeutics Limited
Pfizer Inc.
제15장 전략적 제안
제16장 조사 회사 소개 및 면책사항
ksm
영문 목차
영문목차
Global Myelodysplastic Syndrome (MDS) Treatment Market was valued at USD 2.95 Billion in 2024 and is expected to reach USD 4.20 Billion by 2030 with a CAGR of 6.02% during the forecast period. Myelodysplastic Syndrome (MDS) is a group of blood disorders characterized by dysfunctional blood cell production in the bone marrow. It affects the production of red blood cells, white blood cells, and platelets, leading to a variety of symptoms and complications. Over the years, significant progress has been made in the diagnosis and treatment of MDS, leading to a growing global market for MDS treatment. MDS primarily affects older adults, but it can occur at any age. It is often considered a pre-leukemic condition because it can progress to acute myeloid leukemia (AML). The exact cause of MDS is still unknown, but it is believed to be linked to genetic mutations, exposure to certain chemicals, and radiation therapy.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 2.95 Billion
Market Size 2030
USD 4.20 Billion
CAGR 2025-2030
6.02%
Fastest Growing Segment
Hospitals & Clinics
Largest Market
North America
The Global Myelodysplastic Syndrome (MDS) Treatment Market is witnessing steady growth, driven by several factors. As the global population continues to age, the incidence of MDS is expected to rise. This demographic shift contributes to an increased demand for MDS treatments. Growing awareness among healthcare providers and patients about MDS has led to earlier diagnosis and intervention, further boosting the market's growth. Developing economies are becoming more significant players in the MDS treatment market due to improvements in healthcare infrastructure and access to advanced therapies. Continued investments in MDS research and development by pharmaceutical companies and government agencies are expected to yield innovative treatment options and expand the market.
The global Myelodysplastic Syndrome treatment market has witnessed remarkable advancements in recent years, offering new hope to patients diagnosed with this challenging condition. Targeted therapies, personalized medicine, improved supportive care, and ongoing clinical trials are transforming the landscape of MDS treatment. With a growing aging population and increasing awareness, the market for MDS treatments is poised for continued expansion, ultimately leading to better outcomes and improved quality of life for patients battling this disease.
Key Market Drivers
Rising Prevalence of Respiratory Diseases is Driving the Global Myelodysplastic Syndrome (MDS) Treatment Market
Respiratory diseases have become a significant global health concern, affecting millions of individuals worldwide. These ailments, which include conditions like asthma, chronic obstructive pulmonary disease (COPD), and bronchitis, can severely impact a person's quality of life and, in some cases, be life-threatening. The rising prevalence of respiratory diseases has led to increased demand for effective treatment options, and one such solution that has gained prominence in recent years is Myelodysplastic Syndrome (MDS) Treatment. Myelodysplastic Syndrome (MDS) Treatment are a form of medication delivery that involves inhaling a nebulized solution through a specialized device. This method is particularly effective for delivering medication directly to the respiratory system, making it a vital component in managing and treating respiratory diseases. The global Myelodysplastic Syndrome (MDS) Treatment market has witnessed significant growth in response to the increasing burden of respiratory diseases. In February 2024, Fortis Healthcare in Mumbai achieved a significant milestone, completing 100 bone marrow transplants, a key treatment for myelodysplastic syndrome, leukemia, and other blood disorders. This accomplishment, along with similar advancements and initiatives, is anticipated to drive growth in the market.
Key Market Challenges
Pricing Pressures
Pricing pressures are a significant challenge in the Myelodysplastic Syndrome (MDS) treatment market as healthcare systems across the globe implement increasingly stringent cost-containment measures. Governments, insurance companies, and payers are placing greater emphasis on cost-effectiveness and value-based healthcare, leading to heightened scrutiny of treatment costs and the value they offer. Pharmaceutical companies are under considerable pressure to demonstrate the clinical and economic value of their products in order to secure reimbursement and negotiate favorable pricing terms. In addition, these companies are tasked with finding ways to lower the overall cost of treatment for patients, including offering more affordable treatment options, exploring alternative delivery methods, or reducing the complexity and duration of therapy. The growing demand for cost-effective solutions is driving the need for innovations that deliver both clinical efficacy and economic viability, compelling drug manufacturers to focus on value-based pricing models that align with payer expectations.
Key Market Trends
Technological Advancements
Technological advancements have consistently played a pivotal role in transforming the landscape of healthcare. One such domain where this transformation is prominently visible is in the treatment of Myelodysplastic Syndrome (MDS), a group of bone marrow disorders that hinder the production of healthy blood cells. The Global Myelodysplastic Syndrome (MDS) Treatment Market is experiencing a significant boost, thanks to the remarkable strides made in technology and research. In March 2020, Gilead Sciences, Inc. and Forty-Seven, Inc. have finalized a deal in which Gilead will purchase Forty-Seven at a price of $95.50 per share in cash. Magrolimab is the primary experimental product being developed by Forty-Seven.
One of the most significant breakthroughs in MDS treatment has been the ability to conduct comprehensive genetic profiling of patients. Advanced genomic sequencing technologies enable doctors to identify specific genetic mutations that drive the development of MDS. This information is crucial in tailoring personalized treatment plans and predicting disease progression accurately. With a better understanding of the genetic basis of MDS, pharmaceutical companies are developing targeted therapies that specifically address the underlying genetic abnormalities. These therapies are more effective and have fewer side effects compared to traditional chemotherapy.
Key Market Players
AbbVie Inc.
Accord Healthcare Limited
Bristol-Myers Squibb Company
Jazz Pharmaceuticals Inc.
Novartis AG
Lupin Limited
Otsuka America Pharmaceutical Inc.
Takeda Pharmaceutical Company Limited
Astex Therapeutics Limited
Pfizer Inc.
Report Scope:
In this report, the Global Myelodysplastic Syndrome (MDS) Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Myelodysplastic Syndrome (MDS) Treatment Market, By Treatment Type:
Stem Cell Transplant
Immune Treatments
Chemotherapy
Immunomodulatory Drugs
Anti-Anaemics
Others
Myelodysplastic Syndrome (MDS) Treatment Market, By End User:
Hospitals & Clinics
Ambulatory Care Centers
Others
Myelodysplastic Syndrome (MDS) Treatment Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Myelodysplastic Syndrome (MDS) Treatment Market.
Available Customizations:
Global Myelodysplastic Syndrome (MDS) Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Myelodysplastic Syndrome (MDS) Treatment Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Treatment Type (Stem Cell Transplant, Immune Treatments, Chemotherapy, Immunomodulatory Drugs, Anti-anemics, Others)
5.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. North America Myelodysplastic Syndrome (MDS) Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Treatment Type
6.2.2. By End User
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Myelodysplastic Syndrome (MDS) Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Treatment Type
6.3.1.2.2. By End User
6.3.2. Canada Myelodysplastic Syndrome (MDS) Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Treatment Type
6.3.2.2.2. By End User
6.3.3. Mexico Myelodysplastic Syndrome (MDS) Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Treatment Type
6.3.3.2.2. By End User
7. Europe Myelodysplastic Syndrome (MDS) Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Treatment Type
7.2.2. By End User
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Myelodysplastic Syndrome (MDS) Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Treatment Type
7.3.1.2.2. By End User
7.3.2. United Kingdom Myelodysplastic Syndrome (MDS) Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Treatment Type
7.3.2.2.2. By End User
7.3.3. Italy Myelodysplastic Syndrome (MDS) Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Treatment Type
7.3.3.2.2. By End User
7.3.4. France Myelodysplastic Syndrome (MDS) Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Treatment Type
7.3.4.2.2. By End User
7.3.5. Spain Myelodysplastic Syndrome (MDS) Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Treatment Type
7.3.5.2.2. By End User
8. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Treatment Type
8.2.2. By End User
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Myelodysplastic Syndrome (MDS) Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Treatment Type
8.3.1.2.2. By End User
8.3.2. India Myelodysplastic Syndrome (MDS) Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Treatment Type
8.3.2.2.2. By End User
8.3.3. Japan Myelodysplastic Syndrome (MDS) Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Treatment Type
8.3.3.2.2. By End User
8.3.4. South Korea Myelodysplastic Syndrome (MDS) Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Treatment Type
8.3.4.2.2. By End User
8.3.5. Australia Myelodysplastic Syndrome (MDS) Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Treatment Type
8.3.5.2.2. By End User
9. South America Myelodysplastic Syndrome (MDS) Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Treatment Type
9.2.2. By End User
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Myelodysplastic Syndrome (MDS) Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Treatment Type
9.3.1.2.2. By End User
9.3.2. Argentina Myelodysplastic Syndrome (MDS) Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Treatment Type
9.3.2.2.2. By End User
9.3.3. Colombia Myelodysplastic Syndrome (MDS) Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Treatment Type
9.3.3.2.2. By End User
10. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Treatment Type
10.2.2. By End User
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Myelodysplastic Syndrome (MDS) Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Treatment Type
10.3.1.2.2. By End User
10.3.2. Saudi Arabia Myelodysplastic Syndrome (MDS) Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Treatment Type
10.3.2.2.2. By End User
10.3.3. UAE Myelodysplastic Syndrome (MDS) Treatment Market Outlook
